BioSante Pharmaceuticals, Inc. To Present LibiGel Clinical Trial Update at North American Menopause Society Meeting
BioSante also to sponsor symposium entitled, “Sexual Quality of Life with Aging”
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Oct 4, 2010 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will present a LibiGel clinical trial update at the 21st Annual Meeting of The North American Menopause Society (NAMS) being held from October 6-9, 2010 at the Sheraton Chicago Hotel & Towers in Chicago, Illinois. More than 1,000 experts and practitioners in menopause and women's health are expected to attend the meeting.
Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, will deliver an oral presentation entitled, “LibiGel® (testosterone gel) Safety Study Continues with a Low Rate of Cardiovascular and Breast Cancer Events,” on October 8, 2010 at 4:15 pm CT. Dr. Snabes will present an update on the largest-ever study comparing low-dose testosterone treatment to placebo treatment. To date, this ongoing study has enrolled more than 2,300 menopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD).
In addition, BioSante is sponsoring a symposium entitled, “Sexual Quality of Life with Aging.” The moderator of the symposium is Jan L. Shifren, MD, NCMP, Associate Professor of Obstetrics, Gynecology, & Reproductive Biology at Harvard Medical School, as well as Director of the Menopause Program at Massachusetts General Hospital. The symposium will feature Raymond C. Rosen, PhD, Professor of Psychology at the Robert Wood Johnson Medical School in New Jersey, speaking on the “Prevalence of Sexual Function & Distress Across the Lifespan for Women.” Sheryl A. Kingsberg, PhD, Division Chief, Obstetrics & Gynecology, Behavior Medicine at the University Hospitals Case Medical Center, and Professor, Case Western Reserve University in Cleveland, Ohio will cover the topic entitled, “Treatment Options for Postmenopausal Women With Sexual Dysfunction.” These informative presentations will be followed by a panel discussion involving the speakers and the moderator.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Posted: October 2010